NYSE:BMY - Bristol-Myers Squibb Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $50.98 +0.85 (+1.70 %) (As of 02/22/2019 04:00 PM ET)Previous Close$50.98Today's Range$50.13 - $51.0452-Week Range$44.30 - $68.88Volume14.91 million shsAverage Volume14.49 million shsMarket Capitalization$83.21 billionP/E Ratio12.81Dividend Yield3.27%Beta0.83 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; Tsinghua University; Sirenas; Vedanta Biosciences, Inc.; Mirati Therapeutics, Inc.; and Boston Medical Center. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York. Receive BMY News and Ratings via Email Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNYSE:BMY Previous Symbol CUSIP11012210 CIK14272 Webwww.bms.com Phone212-546-4000Debt Debt-to-Equity Ratio0.41 Current Ratio1.53 Quick Ratio1.40Price-To-Earnings Trailing P/E Ratio12.81 Forward P/E Ratio12.28 P/E Growth2.21 Sales & Book Value Annual Sales$22.56 billion Price / Sales3.69 Cash Flow$3.5775 per share Price / Cash Flow14.25 Book Value$7.24 per share Price / Book7.04Profitability EPS (Most Recent Fiscal Year)$3.98 Net Income$4.95 billion Net Margins21.95% Return on Equity50.03% Return on Assets19.66%Miscellaneous Employees23,700 Outstanding Shares1,632,200,000Market Cap$83.21 billion Next Earnings Date4/25/2019 (Estimated) OptionableOptionable Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions What is Bristol-Myers Squibb's stock symbol? Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY." How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb? Bristol-Myers Squibb declared a quarterly dividend on Thursday, December 6th. Stockholders of record on Friday, January 4th will be paid a dividend of $0.41 per share on Friday, February 1st. This represents a $1.64 annualized dividend and a dividend yield of 3.22%. The ex-dividend date of this dividend is Thursday, January 3rd. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.40. View Bristol-Myers Squibb's Dividend History. How were Bristol-Myers Squibb's earnings last quarter? Bristol-Myers Squibb Co (NYSE:BMY) announced its earnings results on Thursday, January, 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.09. The biopharmaceutical company had revenue of $5.97 billion for the quarter, compared to analysts' expectations of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 50.03%. The company's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.68 earnings per share. View Bristol-Myers Squibb's Earnings History. When is Bristol-Myers Squibb's next earnings date? Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Bristol-Myers Squibb. What guidance has Bristol-Myers Squibb issued on next quarter's earnings? Bristol-Myers Squibb issued an update on its FY19 earnings guidance on Thursday, January, 24th. The company provided earnings per share guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus estimate of $4.18. Bristol-Myers Squibb also updated its FY 2019 guidance to $4.10-4.20 EPS. What price target have analysts set for BMY? 19 equities research analysts have issued 12 month price objectives for Bristol-Myers Squibb's stock. Their predictions range from $47.00 to $74.00. On average, they anticipate Bristol-Myers Squibb's share price to reach $59.3620 in the next year. This suggests a possible upside of 16.4% from the stock's current price. View Analyst Price Targets for Bristol-Myers Squibb. What is the consensus analysts' recommendation for Bristol-Myers Squibb? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 12 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bristol-Myers Squibb. Has Bristol-Myers Squibb been receiving favorable news coverage? News headlines about BMY stock have trended somewhat negative recently, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bristol-Myers Squibb earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near future. Are investors shorting Bristol-Myers Squibb? Bristol-Myers Squibb saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 57,526,799 shares, an increase of 18.9% from the January 15th total of 48,401,111 shares. Based on an average daily volume of 15,761,533 shares, the days-to-cover ratio is currently 3.6 days. Approximately 3.5% of the company's stock are short sold. View Bristol-Myers Squibb's Current Options Chain. Who are some of Bristol-Myers Squibb's key competitors? Some companies that are related to Bristol-Myers Squibb include Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bayer (BAYRY), Celgene (CELG), Shire (SHPG) and Vertex Pharmaceuticals (VRTX). What other stocks do shareholders of Bristol-Myers Squibb own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include Gilead Sciences (GILD), Pfizer (PFE), General Electric (GE), AT&T (T), Intel (INTC), AbbVie (ABBV), Johnson & Johnson (JNJ), Bank of America (BAC), Cisco Systems (CSCO) and Verizon Communications (VZ). Who are Bristol-Myers Squibb's key executives? Bristol-Myers Squibb's management team includes the folowing people: Dr. Giovanni Caforio, Chairman & CEO (Age 54)Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)Dr. Thomas J. Lynch Jr., Exec. VP of R&D & Chief Scientific Officer (Age 58)Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57) Who are Bristol-Myers Squibb's major shareholders? Bristol-Myers Squibb's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.08%), Northern Trust Corp (1.38%), Geode Capital Management LLC (1.24%), Bank of New York Mellon Corp (1.06%), Jennison Associates LLC (0.68%) and Massachusetts Financial Services Co. MA (0.60%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb. Which major investors are selling Bristol-Myers Squibb stock? BMY stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Canada Pension Plan Investment Board, Parnassus Investments CA, Orbimed Advisors LLC, State of Tennessee Treasury Department, Hexavest Inc., Harris Associates L P and Great West Life Assurance Co. Can. View Insider Buying and Selling for Bristol-Myers Squibb. Which major investors are buying Bristol-Myers Squibb stock? BMY stock was bought by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, MERIAN GLOBAL INVESTORS UK Ltd, Prudential Financial Inc., Two Sigma Advisers LP, Los Angeles Capital Management & Equity Research Inc., Carmignac Gestion, BlackRock Inc. and Northern Trust Corp. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb. How do I buy shares of Bristol-Myers Squibb? Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Bristol-Myers Squibb's stock price today? One share of BMY stock can currently be purchased for approximately $50.98. How big of a company is Bristol-Myers Squibb? Bristol-Myers Squibb has a market capitalization of $83.21 billion and generates $22.56 billion in revenue each year. The biopharmaceutical company earns $4.95 billion in net income (profit) each year or $3.98 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe. What is Bristol-Myers Squibb's official website? The official website for Bristol-Myers Squibb is http://www.bms.com. How can I contact Bristol-Myers Squibb? Bristol-Myers Squibb's mailing address is 430 E. 29th Street 14 Floor, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected] MarketBeat Community Rating for Bristol-Myers Squibb (NYSE BMY)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 890 (Vote Outperform)Underperform Votes: 823 (Vote Underperform)Total Votes: 1,713MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2019 by MarketBeat.com StaffFeatured Article: Why is the price-sales ratio important?